SCHEMBL5542584

SCHEMBL5542584

Cc1ccc(CN[CH]c2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.49
HTT P42858 1/20 0.48
NPC1 O15118 2/20 0.47
HPGD P15428 2/20 0.47
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
ADH1B P00325 1/20 0.44
ADH1C P00326 1/20 0.44
ADH1A P07327 1/20 0.44
ADH7 P40394 1/20 0.44
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
TP53 P04637 1/20 0.44
ACHE P22303 3/20 0.42
LMNA P02545 2/20 0.42
TSHR P16473 1/20 0.42
ALOX12 P18054 1/20 0.42
CA12 O43570 1/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7385255 0.86 ADH1B (0.58) HPGDALDH1A1MAPTADH1BADH1C
SCHEMBL5544036 0.83 TACR1 (0.39) SMN1; SMN2NPC1HPGDRAB9AALDH1A1
SCHEMBL5545644 0.81 ACHE (0.48) HTTHPGDALDH1A1MAPTADH1B
SCHEMBL5539505 0.81 LMNA (0.50) HPGDALDH1A1ADH1BADH1CADH1A
SCHEMBL5534736 0.81 PLA2G1B (0.49) NPC1HPGDRAB9AALDH1A1ADH1B
SCHEMBL5544677 0.81 L3MBTL1 (0.45) HTTHPGDALDH1A1ADH1BADH1C
SCHEMBL5546127 0.81 ADH1B (0.44) RAB9AALDH1A1MAPTADH1BADH1C
SCHEMBL5537515 0.80 RAB9A (0.48) SMN1; SMN2HTTNPC1RAB9AALDH1A1
SCHEMBL5544473 0.80 RAB9A (0.57) SMN1; SMN2HTTNPC1RAB9AALDH1A1
SCHEMBL5544592 0.76 RAB9A (0.52) SMN1; SMN2NPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885HTT 4644/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.